Abstract
Background: Rheumatic diseases have many hematological manifestations. Blood dyscrasias and other hematological abnormalities are sometimes the first sign of rheumatic disease. In addition, novel antirheumatic biological agents may cause cytopenias. Summary: The aim of this review was to discuss cytopenias caused by systemic lupus erythematosus and antirheumatic drugs, Felty’s syndrome in rheumatoid arthritis, and autoimmune hemolytic anemia, thrombosis, and thrombotic microangiopathies related to rheumatological conditions such as catastrophic antiphospholipid syndrome and scleroderma renal crisis. Key Message: The differential diagnosis of various hematological disorders should include rheumatic autoimmune diseases among other causes of blood cell and hemostasis abnormalities. It is crucial that hematologists be aware of these presentations so that they are diagnosed and treated in a timely manner.
References
1.
Keeling
DM
, Isenberg
DA
. Haematological manifestations of systemic lupus erythematosus
. Blood Rev
. 1993
;7
(4
):199
–207
. .2.
Nossent
JC
, Swaak
AJ
. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus
. Q J Med
. 1991
;80
(291
):605
–12
.3.
Tan
EM
, Cohen
AS
, Fries
JF
, Masi
AT
, McShane
DJ
, Rothfield
NF
, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus
. Arthritis Rheum
. 1982 Nov
;25
(11
):1271
–7
. .4.
Petri
M
, Orbai
AM
, Alarcón
GS
, Gordon
C
, Merrill
JT
, Fortin
PR
, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
. Arthritis Rheum
. 2012 Aug
;64
(8
):2677
–86
. .5.
Levine
AB
, Erkan
D
. Clinical assessment and management of cytopenias in lupus patients
. Curr Rheumatol Rep
. 2011 Aug
;13
(4
):291
–9
. .6.
Dias
AM
, do Couto
MC
, Duarte
CC
, Inês
LP
, Malcata
AB
. White blood cell count abnormalities and infections in one-year follow-up of 124 patients with SLE
. Ann N Y Acad Sci
. 2009 Sep
;1173
:103
–7
. .7.
Rivero
SJ
, Díaz-Jouanen
E
, Alarcón-Segovia
D
. Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance
. Arthritis Rheum
. 1978 Apr
;21
(3
):295
–305
. .8.
Schulze-Koops
H
. Lymphopenia and autoimmune diseases
. Arthritis Res Ther
. 2004
;6
(4
):178
–80
. .9.
Fayyaz
A
, Igoe
A
, Kurien
BT
, Danda
D
, James
JA
, Stafford
HA
, et al. Haematological manifestations of lupus
. Lupus Sci Med
. 2015 Mar 3
;2
(1
):e000078
. .10.
Klein
A
, Polliack
A
, Gafter-Gvili
A
. Systemic lupus erythematosus and lymphoma: incidence, pathogenesis and biology
. Leuk Res
. 2018 Dec
;75
:45
–9
. .11.
Beyan
E
, Beyan
C
, Turan
M
. Hematological presentation in systemic lupus erythematosus and its relationship with disease activity
. Hematology
. 2007
;12
(3
):257
–61
. .12.
Miranda-Hernández
D
, Cruz-Reyes
C
, Monsebaiz-Mora
C
, Gómez-Bañuelos
E
, Ángeles
U
, Jara
LJ
, et al. Active haematological manifestations of systemic lupus erythematosus lupus are associated with a high rate of in-hospital mortality
. Lupus
. 2017
;26
(6
):640
–5
. .13.
Meyer
A
, Guffroy
A
, Blaison
G
, Dieudonne
Y
, Amoura
Z
, Bonnotte
B
, et al. Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations
. Lupus Sci Med
. 2020
;7
(1
):e000399
. .14.
Atallah-Yunes
SA
, Ready
A
, Newburger
PE
. Benign ethnic neutropenia
. Blood Rev
. 2019
;37
:100586
. .15.
Carli
L
, Tani
C
, Vagnani
S
, Signorini
V
, Mosca
M
. Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact: a systematic literature review
. Semin Arthritis Rheum
. 2015 Oct
;45
(2
):190
–4
.16.
Newman
KA
, Akhtari
M
. Management of autoimmune neutropenia in Felty’s syndrome and systemic lupus erythematosus
. Autoimmun Rev
. 2011 May
;10
(7
):432
–7
. .17.
Hellmich
B
, Schnabel
A
, Gross
WL
. Treatment of severe neutropenia due to Felty’s syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor
. Semin Arthritis Rheum
. 1999 Oct
;29
(2
):82
–99
. .18.
Owlia
MB
, Newman
K
, Akhtari
M
. Felty’s syndrome, insights and updates
. Open Rheumatol J
. 2014
;8
:129
–36
. .19.
Jain
T
, Mittal
C
, Sengupta
R
, Rubin
B
. Non-articular Felty’s syndrome: an uncommon diagnosis
. Neth J Med
. 2015 Nov
;73
(9
):435
–6
.20.
Bowman
SJ
. Hematological manifestations of rheumatoid arthritis
. Scand J Rheumatol
. 2002
;31
(5
):251
–9
. .21.
Balint
GP
, Balint
PV
. Felty’s syndrome
. Best Pract Res Clin Rheumatol
. 2004 Oct
;18
(5
):631
–45
. .22.
Narváez
J
, Domingo-Domenech
E
, Gómez-Vaquero
C
, López-Vives
L
, Estrada
P
, Aparicio
M
, et al. Biological agents in the management of Felty’s syndrome: a systematic review
. Semin Arthritis Rheum
. 2012 Apr
;41
(5
):658
–68
. .23.
Heylen
L
, Dierickx
D
, Vandenberghe
P
, Westhovens
R
. Targeted herapy with rituximab in Felty’s syndrome: a case report
. Open Rheumatol J
. 2012
;6
:312
–4
.24.
Lee
EJ
, Lee
AI
. Thrombocytopenia
. Prim Care
. 2016 Dec
;43
(4
):543
–57
. .25.
Fernández
M
, Alarcón
GS
, Apte
M
, Andrade
RM
, Vilá
LM
, Reveille
JD
. Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor
. Arthritis Rheum
. 2007 Feb
;56
(2
):614
–21
. .26.
Kado
R
, McCune
WJ
. Treatment of primary and secondary immune thrombocytopenia
. Curr Opin Rheumatol
. 2019
;31
(3
):213
–22
. .27.
Arnal
C
, Piette
JC
, Léone
J
, Taillan
B
, Hachulla
E
, Roudot-Thoraval
F
, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases
. J Rheumatol
. 2002 Jan
;29
(1
):75
–83
.28.
Newman
K
, Owlia
MB
, El-Hemaidi
I
, Akhtari
M
. Management of immune cytopenias in patients with systemic lupus erythematosus: old and new
. Autoimmun Rev
. 2013
;12
(7
):784
–91
. .29.
Cobo-Ibáñez
T
, Loza-Santamaría
E
, Pego-Reigosa
JM
, Marqués
AO
, Rúa-Figueroa
I
, Fernández-Nebro
A
, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review
. Semin Arthritis Rheum
. 2014 Oct
;44
(2
):175
–85
. .30.
Serris
A
, Amoura
Z
, Canouï-Poitrine
F
, Terrier
B
, Hachulla
E
, Costedoat-Chalumeau
N
, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults
. Am J Hematol
. 2018 Mar
;93
(3
):424
–9
. .31.
Shobha
V
, Sanil
S
, Roongta
R
. Eltrombopag: efficacy and safety in steroid refractory lupus-associated immune thrombocytopenia
. J Clin Rheumatol
. 2020 Oct
;26
(7
):274
–8
.32.
Lusa
A
, Carlson
A
. Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series
. Lupus
. 2018 Sep
;27
(10
):1723
–8
. .33.
Uthman
I
, Godeau
B
, Taher
A
, Khamashta
M
. The hematologic manifestations of the antiphospholipid syndrome
. Blood Rev
. 2008 Jul
;22
(4
):187
–94
. .34.
Rattarittamrong
E
, Eiamprapai
P
, Tantiworawit
A
, Rattanathammethee
T
, Hantrakool
S
, Chai-Adisaksopha
C
, et al. Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia
. Hematology
. 2016 Jul
;21
(6
):368
–74
. .35.
Costallat
GL
, Appenzeller
S
, Costallat
LT
. Evans syndrome and systemic lupus erythematosus: clinical presentation and outcome
. Joint Bone Spine
. 2012 Jul
;79
(4
):362
–4
. .36.
Velo-García
A
, Castro
SG
, Isenberg
DA
. The diagnosis and management of the haematologic manifestations of lupus
. J Autoimmun
. 2016 Nov
;74
:139
–60
. .37.
Gormezano
NW
, Kern
D
, Pereira
OL
, Esteves
GC
, Sallum
AM
, Aikawa
NE
, et al. Autoimmune hemolytic anemia in systemic lupus erythematosus at diagnosis: differences between pediatric and adult patients
. Lupus
. 2017 Apr
;26
(4
):426
–30
. .38.
Skare
T
, Picelli
L
, Dos Santos
TAG
, Nisihara
R
. Direct antiglobulin (Coombs) test in systemic lupus erythematosus patients
. Clin Rheumatol
. 2017 Sep
;36
(9
):2141
–4
. .39.
Go
RS
, Winters
JL
, Kay
NE
. How I treat autoimmune hemolytic anemia
. Blood
. 2017 Jun 1
;129
(22
):2971
–9
. .40.
Reynaud
Q
, Durieu
I
, Dutertre
M
, Ledochowski
S
, Durupt
S
, Michallet
AS
, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies
. Autoimmun Rev
. 2015 Apr
;14
(4
):304
–13
. .41.
Rajakulendran
S
, Gadsby
K
, Allen
D
, O’Reilly
S
, Deighton
C
. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis
. Ann Rheum Dis
. 2006 Dec
;65
(12
):1678
–9
. .42.
Hastings
R
, Ding
T
, Butt
S
, Gadsby
K
, Zhang
W
, Moots
RJ
, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy
. Arthritis Care Res
. 2010 Jun
;62
(6
):764
–9
. .43.
Azevedo
VF
, Silva
MB
, Marinello
DK
, Santos
FD
, Silva
GB
. Leukopenia and thrombocytopenia induced by etanercept: two case reports and literature review
. Rev Bras Reumatol
. 2012 Jan–Feb
;52
(1
):110
–2
. .44.
He
Y
, Sawalha
AH
. Drug-induced lupus erythematosus: an update on drugs and mechanisms
. Curr Opin Rheumatol
. 2018
;30
(5
):490
–7
. .45.
Ramos-Casals
M
, Roberto-Perez-Alvarez
R
, Diaz-Lagares
C
, Cuadrado
MJ
, Khamashta
MA
; BIOGEAS Study Group
. Autoimmune diseases induced by biological agents: a double-edged sword?
Autoimmun Rev
. 2010 Jan
;9
(3
):188
–93
. .46.
Salmon
JH
, Cacoub
P
, Combe
B
, Sibilia
J
, Pallot-Prades
B
, Fain
O
, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab Registry
. RMD Open
. 2015 Jun 30
;1
(1
):e000034
. .47.
Monaco
WE
, Jones
JD
, Rigby
WF
. Rituximab associated late-onset neutropenia: a rheumatology case series and review of the literature
. Clin Rheumatol
. 2016 Oct
;35
(10
):2457
–62
. .48.
Tesfa
D
, Ajeganova
S
, Hägglund
H
, Sander
B
, Fadeel
B
, Hafström
I
, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections
. Arthritis Rheum
. 2011 Aug
;63
(8
):2209
–14
. .49.
Schulze-Koops
H
, Strand
V
, Nduaka
C
, DeMasi
R
, Wallenstein
G
, Kwok
K
, et al. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies
. Rheumatology
. 2017 Jan
;56
(1
):46
–57
. .50.
Ogata
A
, Kato
Y
, Higa
S
, Yoshizaki
K
. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review
. Mod Rheumatol
. 2019 Mar
;29
(2
):258
–67
. .51.
Emmi
G
, Silvestri
E
, Squatrito
D
, Amedei
A
, Niccolai
E
, D’Elios
MM
, et al. Thrombosis in vasculitis: from pathogenesis to treatment
. Thromb J
. 2015 Apr 16
;13
:15
. .52.
Katz
OB
, Brenner
B
, Horowitz
NA
. Thrombosis in vasculitic disorders-clinical manifestations, pathogenesis and management
. Thromb Res
. 2015 Sep
;136
(3
):504
–12
. .53.
Morgan
MD
, Turnbull
J
, Selamet
U
, Kaur-Hayer
M
, Nightingale
P
, Ferro
CJ
, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study
. Arthritis Rheum
. 2009 Nov
;60
(11
):3493
–500
. .54.
Allenbach
Y
, Seror
R
, Pagnoux
C
, Teixeira
L
, Guilpain
P
, Guillevin
L
, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients
. Ann Rheum Dis
. 2009 Apr
;68
(4
):564
–7
. .55.
Stassen
PM
, Derks
RP
, Kallenberg
CG
, Stegeman
CA
. Venous thromboembolism in ANCA-associated vasculitis: incidence and risk factors
. Rheumatology
. 2008 Apr
;47
(4
):530
–4
. .56.
Gonzalez-Gay
MA
, Vazquez-Rodriguez
TR
, Gomez-Acebo
I
, Pego-Reigosa
R
, Lopez-Diaz
MJ
, Vazquez-Triñanes
MC
, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis
. Medicine
. 2009 Jul
;88
(4
):227
–35
. .57.
Duarte
MM
, Geraldes
R
, Sousa
R
, Alarcão
J
, Costa
J
. Stroke and transient ischemic attack in Takayasu’s arteritis: a systematic review and meta-analysis
. J Stroke Cerebrovasc Dis
. 2016 Apr
;25
(4
):781
–91
. .58.
Aviña-Zubieta
JA
, Bhole
VM
, Amiri
N
, Sayre
EC
, Choi
HK
. The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study
. Ann Rheum Dis
. 2016 Jan
;75
(1
):148
–54
. .59.
Unizony
S
, Lu
N
, Tomasson
G
, Zhang
Y
, Merkel
PA
, Stone
JH
, et al. Temporal trends of venous thromboembolism risk before and after diagnosis of giant cell arteritis
. Arthritis Rheumatol
. 2017 Jan
;69
(1
):176
–84
. .60.
Chung
WS
, Peng
CL
, Lin
CL
, Chang
YJ
, Chen
YF
, Chiang
JY
, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study
. Ann Rheum Dis
. 2014 Oct
;73
(10
):1774
–80
. .61.
Matta
F
, Singala
R
, Yaekoub
AY
, Najjar
R
, Stein
PD
. Risk of venous thromboembolism with rheumatoid arthritis
. Thromb Haemost
. 2009 Jan
;101
(1
):134
–8
. .62.
Holmqvist
ME
, Neovius
M
, Eriksson
J
, Mantel
Ä
, Wållberg-Jonsson
S
, Jacobsson
LT
, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization
. JAMA
. 2012 Oct 3
;308
(13
):1350
–6
. .63.
Ogdie
A
, Kay McGill
N
, Shin
DB
, Takeshita
J
, Jon Love
T
, Noe
MH
, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study
. Eur Heart J
. 2018 Oct 14
;39
(39
):3608
–14
. .64.
65.
Bazzan
M
, Vaccarino
A
, Marletto
F
. Systemic lupus erythematosus and thrombosis
. Thromb J
. 2015 Apr 23
;13
:16
. .66.
Hinojosa-Azaola
A
, Romero-Diaz
J
, Vargas-Ruiz
AG
, Nuñez-Alvarez
CA
, Cicero-Casarrubias
A
, Ocampo-Torres
MC
, et al. Venous and arterial thrombotic events in systemic lupus erythematosus
. J Rheumatol
. 2016 Mar
;43
(3
):576
–86
. .67.
Sarabi
ZS
, Chang
E
, Bobba
R
, Ibanez
D
, Gladman
D
, Urowitz
M
, et al. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus
. Arthritis Rheum
. 2005 Aug 15
;53
(4
):609
–12
. .68.
George
JN
, Nester
CM
. Syndromes of thrombotic microangiopathy
. N Engl J Med
. 2014 Aug 14
;371
(19
):1847
–8
. .69.
Mouthon
L
, Bussone
G
, Berezné
A
, Noël
LH
, Guillevin
L
. Scleroderma renal crisis
. J Rheumatol
. 2014 Jun
;41
(6
):1040
–8
. .70.
Babar
F
, Cohen
SD
. Thrombotic microangiopathies with rheumatologic involvement
. Rheum Dis Clin North Am
. 2018 Nov
;44
(4
):635
–49
. .71.
Bose
N
, Chiesa-Vottero
A
, Chatterjee
S
. Scleroderma renal crisis
. Semin Arthritis Rheum
. 2015 Jun
;44
(6
):687
–94
. .72.
Butler
EA
, Baron
M
, Fogo
AB
, Frech
T
, Ghossein
C
, Hachulla
E
, et al. Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group. Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology
. Arthritis Rheumatol
. 2019 Jun
;71
(6
):964
–71
.73.
Kowal-Bielecka
O
, Fransen
J
, Avouac
J
, Becker
M
, Kulak
A
, Allanore
Y
, et al. Update of EULAR recommendations for the treatment of systemic sclerosis
. Ann Rheum Dis
. 2017 Aug
;76
(8
):1327
–39
. .74.
Rodríguez-Pintó
I
, Espinosa
G
, Cervera
R
. Catastrophic APS in the context of other thrombotic microangiopathies
. Curr Rheumatol Rep
. 2015 Jan
;17
(1
):482
. .75.
Asherson
RA
, Cervera
R
, de Groot
PG
, Erkan
D
, Boffa
MC
, Piette
JC
, et al. Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines
. Lupus
. 2003
;12
(7
):530
–4
.76.
Ortel
TL
, Erkan
D
, Kitchens
CS
. How I treat catastrophic thrombotic syndromes
. Blood
. 2015 Sep 10
;126
(11
):1285
–93
. .77.
Strakhan
M
, Hurtado-Sbordoni
M
, Galeas
N
, Bakirhan
K
, Alexis
K
, Elrafei
T
. 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature
. Case Rep Hematol
. 2014
;2014
:704371
. .78.
Li
C
, Yap
C
, Chan
G
, Wen
YB
, Li
H
, Tang
C
, et al. Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy
. J Rheumatol
. 2019 Nov
;46
(11
):1478
–84
. .79.
Chen
MH
, Chen
MH
, Chen
WS
, Mu-Hsin Chang
P
, Lee
HT
, Lin
HY
, et al. Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan
. Rheumatology
. 2011 Apr
;50
(4
):768
–75
. .80.
El-Husseini
A
, Hannan
S
, Awad
A
, Jennings
S
, Cornea
V
, Sawaya
BP
. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab
. Am J Kidney Dis
. 2015 Jan
;65
(1
):127
–30
. .© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
